Prognostic scoring models in myelofibrosis
| MYSEC-PM . | MIPSS-70 (Plus) . | GIPSS . |
|---|---|---|
| Age at diagnosis of secondary | Leukocytosis (2 points) or leukopenia | ASXL1 mutation |
| MF | ||
| Anemia | Anemia | SRSF2 mutation |
| Thrombocytopenia | Thrombocytopenia (2 points) | U2AF1Q157 mutation |
| CALR unmutated genotype | Absence of a CALR type 1–like mutation | Absence of CALR type 1–like mutations |
| Circulating peripheral blasts | Circulating peripheral blasts | Unfavorable karyotype |
| Constitutional symptoms | Constitutional symptoms | Very-high-risk karyotype (2 points) |
| BM fibrosis grade | ||
| IPSS/DIPSS plus category | ||
| MPN phenotypic driver mutation | ||
| HMR mutations (ASXL1, SRSF2, or IDH 1/2) | ||
| HMR category | ||
| Presence of ≥2 HMR mutations (2 points) | ||
| MIPSS- 70 plus only presence of unfavorable karyotype |
| MYSEC-PM . | MIPSS-70 (Plus) . | GIPSS . |
|---|---|---|
| Age at diagnosis of secondary | Leukocytosis (2 points) or leukopenia | ASXL1 mutation |
| MF | ||
| Anemia | Anemia | SRSF2 mutation |
| Thrombocytopenia | Thrombocytopenia (2 points) | U2AF1Q157 mutation |
| CALR unmutated genotype | Absence of a CALR type 1–like mutation | Absence of CALR type 1–like mutations |
| Circulating peripheral blasts | Circulating peripheral blasts | Unfavorable karyotype |
| Constitutional symptoms | Constitutional symptoms | Very-high-risk karyotype (2 points) |
| BM fibrosis grade | ||
| IPSS/DIPSS plus category | ||
| MPN phenotypic driver mutation | ||
| HMR mutations (ASXL1, SRSF2, or IDH 1/2) | ||
| HMR category | ||
| Presence of ≥2 HMR mutations (2 points) | ||
| MIPSS- 70 plus only presence of unfavorable karyotype |
BM, bone marrow.